HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

Benzinga Newsdesk www.benzinga.com Neutral 47.8%

Neg 0% Neu 47.8% Pos 0%

HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.